Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3125-3131

  Pyzer, Athalia R ^a   Avigan, David E ^a   Rosenblatt, Jacalyn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Dendritic cell; Immunotherapy; Leukemia; Myeloma; Trial; Vaccine

Indexed keywords

B CELL MATURATION ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; PLACEBO; RNA; SURVIVIN; TUMOR CELL VACCINE; WT1 PROTEIN; CANCER VACCINE; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE MYELOMA; MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 84921769110     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.982993     Document Type: Article

References (87)

1. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87(5):1710-7; PMID:8634416
2. Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem cells in myeloid malignancy. Oncogene 2013; PMID:23831573
3. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol 2003; 81(2):106-13; PMID:12631233
4. Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2(3):233-42; PMID:3332173
5. Mavroudis D, Barrett J. The graft-versus-leukemia effect. Curr Opin Hematol. 1996 Nov; 3(6):423-9; PMID:9372113
6. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev 2013 Jan; 27(1):55-62; PMID:23261066
7. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71(7):1093-102; PMID:1335364
8. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186(5):645-53; PMID:9271580
9. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002 169(5):2756-61; PMID:12193750
10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12(4):253-68; PMID:22437938
11. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34(5):409-18.PMID:21577144
12. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5):430-9.PMID:21074057
13. Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer 2013; 4(1):36-44; PMID:23386903
14. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008; 65(3):191-9; PMID:18055210
15. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999; 13(1):51-64; PMID:10225609
16. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9 :271-96; PMID:1910679
17. Dubois B, Massacrier C, Caux C. Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol 2001; 70(4):633-41; PMID:11590201
18. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandala M, Barni S, Tancini G, Fumagalli L, Giani L. et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents 1999 1999; 13(4):216-9; PMID:10703945
19. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4(12):941-52; PMID:15573129; http://dx.doi.org/10.1038/nri1498
20. Jonuleit H, Kühn U, M üller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27(12):3135-42; PMID:9464798; http://dx.doi.org/10.1002/eji.1830271209
21. Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJ. Paradigm Shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5 :165; PMID:24782868; http://dx.doi.org/10.3389/fimmu.2014.00165
22. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14(5):483-94; PMID:12691613
23. Avigan DE GD, Kantoff PW, editor Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma2004. J Clin Oncol ASCO Annual Meeting Proceedings.
24. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszy ńska A, Schmitt M. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19(9):1621-7; PMID: 15990861; http://dx.doi.org/10.1038/sj.leu.2403860
25. Philip R, Alters SE, Brunette E, Ashton J, Gadea J, Yau J, Lebkowski J, Philip M. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumorspecific cytotoxic T lymphocyte responses in patients with melanoma. J Immunother 2000; 23(1):168-76; PMID:10687150; http://dx.doi.org/10.1097/00002371-200001000-00020
26. Minev BR, Chavez FL, Dudouet BM,MitchellMS. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. Eur J Immunol 2000; 30(8):2115-24; PMID:10940901; http://dx.doi.org/10.1002/1521-4141(2000)30:8%3c2115::AID-IMMU2115%3e3.0.CO;2-J
27. Cao J, Jin Y, Li W, Zhang B, He Y, Liu H, Xia N, Wei H, Yan J. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol 2013; 14:39.PMID:23941509
28. Li D, Hua S, Fan Y, Xu S, Duan X, Liu L, Che Y, Li S, Tan Y. DNA vaccine expressing repeated carcinoembryonic antigen(CEA)(625-667) induces strong immunity in mice. Immunol Lett 2011; 135(1-2):124-8; PMID:21073899
29. Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, Rinaldi M, Tonon G, Fazio VM. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 2010; 59(10):1583-91; PMID:20390416; http://dx.doi.org/10.1007/s00262-010-0853-x
30. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2):465-72.PMID:8760800
31. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235(4):540-9; PMID:11923611; http://dx.doi.org/10.1097/00000658-200204000-00013
32. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C. et al. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013; PMID:24125763
33. Litzinger MT, Foon KA, Sabzevari H, Tsang KY, Schlom J, Palena C. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Cancer Immunol Immunother 2009; 58(6):955-65; PMID:19009294; http://dx.doi.org/10.1007/s00262-008-0611-5
34. Litzinger MT, Foon KA, Tsang KY, Schlom J, Palena C. Comparative analysis of MVA-CD40L and MVATRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia(CLL) cells. Leuk Res 2010; 34(10):1351-7; PMID:20122733; http://dx.doi.org/10.1016/j.leukres.2009.12.013
35. Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, Rossmann E, Widén K, Horváth R, Kokhaei P, et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies(Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol Immunother 2012;61(6):865-79; PMID:22086161; http://dx.doi.org/10.1007/s00262-011-1149-5
36. Avigan D, Rosenblatt J, Kufe D. Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol 2012; 39(3):287-95; PMID:22595051; http://dx.doi.org/10.1053/j.seminoncol.2012.02.003
37. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2(5):e24437; PMID:23762810; http://dx.doi.org/10.4161/onci.24437
38. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood 2011;118(3):499-509; PMID:21531979
39. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011; 117(2):393-402; PMID:21030562
40. Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC, Chen YB, Ma HQ, Liu Q, Xia JC. et al. Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci 2010; 6(7):639-48.PMID:20975822
41. Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 2012; 170(2):167-77; PMID:23039887
42. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002; 62(10):2861-8; PMID:12019165
43. Kokhaei P, Choudhury A,Mahdian R, Lundin J, Moshfegh A, Osterborg A, Mellstedt H. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18(11):1810-5; PMID:15385926
44. van den Ancker W, Ruben JM, Westers TM, Wulandari D, Bontkes HJ, Hooijberg E, Stam AG, Santegoets SJ, Ossenkoppele GJ, de Gruijl T, et al. Priming of PRAME- and WT1-specific CD8(C) T cells in healthy donors but not in AML patients in complete remission: implications for immunotherapy. Oncoimmunology 2013; 2(4):e23971; PMID:23734332
45. Milazzo C, Reichardt VL, Müller MR, Grünebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumorderived RNA. Blood 2003; 101(3):977-82; PMID:12393470
46. Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13(2 Pt 1):540-9; PMID:17255276
47. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011;17(17):5725-35; PMID:21771874
48. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19(13):3640-8; PMID:23685836
49. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999; 93(7):2411-9; PMID:10090953
50. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99(5):1517-26; PMID:11861263
51. Schuster S, editor Idiotype vaccine therapy(biovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. University of Pennsylvania 2009.
52. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol 2009; 84(12):799-802; PMID:19899131
53. Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idio-type-pulsed dendritic cells. J Immunother 2011; 34(1):100-6; PMID:21150718
54. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, et al. NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105(10):3939-44; PMID:15671442
55. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res 2005; 65(21):10041-9; PMID:16267030
56. Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Döhner K, Döhner H, Dörken B, Pezzutto A. et al. Vaccination with autologous nonirradiated dendritic cells in patients with bcr/ablC chronic myeloid leukaemia. Br J Haematol 2007; 137(4):297-306; PMID:17408402
57. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103(3):1037-42; PMID:14504104
58. Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, et al. Wilms' Tumour 1(WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 2014; 164(3):366-75; PMID:24422723
59. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al. Induction of WT1(wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101(38):13885-90; PMID:15365188
60. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, et al. Immunogenicity of dendritic cells pulsed with MAGE3, survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 2013; 62(8):1381-92.PMID:23728352
61. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107(31):13824-9; PMID:20631300
62. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009; 11(5):653-68; PMID:19530029
63. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Itoh T, Shimizu A, Kuzushima K, Kondo T, et al. Cross-priming of CD8(C) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp Hematol 2011 Apr; 39(4):424-33.e2; PMID:21216276
64. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszy ńska A, Roliński J. et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22(5):1007-17; PMID:18323802
65. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009; 113(1):18-27; PMID:18809757
66. Rosenblatt J, Stone R, Uhl L, Neuberg D, Vasir B, Somaiya P, et al. editors. Clinical trial evaluating DC/ AML fusion cell vaccination in AML patients who achieve a chemotherapy-induced remission. ASH Annual Meeting; 2013; New Orleans Convention Center.
67. Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009; 106(37):15825-30; PMID:19717467
68. Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 2013; 123(9):3756-65; PMID:23912587
69. Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Shimomura T, Kinoshita M, Kawano F. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 1999; 90(10):1117-29; PMID:10595741
70. Stam AG, Santegoets SJ, Westers TM, Sombroek CC, Janssen JJ, Tillman BW, van de Loosdrecht AA, Pinedo HM, Curiel DT, Ossenkoppele GJ, et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer 2003; 89(7):1162-5; PMID:14520439
71. Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 2005; 54(7):685-93; PMID:15627212
72. Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, Ghia P, Caligaris-Cappio F. Leukemiaderived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol 2004;173(4):2855-65; PMID:15295005
73. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 2008; 48(5):861-70; PMID:18208411
74. van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA. Recent advances in antigenloaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy 2010; 2(1):69-83; PMID:20635890
75. Fujii S, Shimizu K, Koji F, Kawano F. Malignant counterpart of myeloid dendritic cell(DC) belonging to acute myelogenous leukemia(AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol 2003; 73(1):82-90; PMID:12525565
76. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006; 8(3):290-8; PMID:16793737
77. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, Waterfall M, Samuel K, Yin J, Johnson P, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 2006; 133(2):152-7.PMID:16611305
78. Houtenbos I, Westers TM, Hess CJ, Waisfisz Q, Ossenkoppele GJ, van de Loosdrecht AA. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia 2006;20(10):1892-5; PMID:16932350
79. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012; 14(6):647-56; PMID:22686130
80. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: mye-loid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138(2):105-15; PMID:23216602
81. Demoulin S, Herfs M, Delvenne P, Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 2013;93(3):343-52; PMID:23136258
82. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7(5):651-8; PMID:21647333
83. Rosenblatt J AI, Vasir B, Uhl L, Katz T, Avigan D et al. editor Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation. ASH 2012 2012.
84. Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother 2010; 59(3):379-88; PMID:19711075
85. Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, et al. Granulocyte-macrophage colonystimulating factor(GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation(ASCT) as postremission therapy for acute myeloid leukemia(AML). Blood 2009; 114(9):1736-45; PMID:19556425
86. Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C. Enhanced cross-priming of naive CD8C T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology 2013; 139(3):377-85; PMID:23374145; http://dx.doi.org/10.1111/imm.12087
87. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62(1):39-49; PMID:22733396; http://dx.doi.org/10.1007/s00262-012-1308-3